How Do Comorbidities Impact Cosentyx Prescribing?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, requires caution or contraindication with certain comorbidities due to infection risks, immune suppression, and drug interactions. Key concerns stem from its black box warning for serious infections like tuberculosis (TB) reactivation.[1]
Active Infections or High Infection Risk
Avoid Cosentyx in patients with active infections, including TB, or those at high risk (e.g., recent exposure, endemic areas). Screen for latent TB before starting; treat if positive. Comorbidities like chronic obstructive pulmonary disease (COPD) with frequent exacerbations or untreated HIV increase opportunistic infection risks, such as candidiasis or sepsis.[1][2]
Inflammatory Bowel Disease (IBD)
Cosentyx can exacerbate Crohn's disease or ulcerative colitis. Use is contraindicated in active IBD; monitor closely in patients with history. Clinical trials showed new-onset or worsening IBD in 1-2% of cases, leading to discontinuation.[1][3]
Liver or Kidney Impairment
No dose adjustment needed for mild-moderate hepatic/renal issues, but data are limited in severe cases (Child-Pugh C or eGFR <30 mL/min). Comorbidities like cirrhosis or end-stage renal disease warrant specialist review due to potential accumulation and heightened infection risk.[1][4]
Malignancy History
Avoid in active cancer or recent malignancy (within 5 years, except non-melanoma skin cancer). Comorbidities like lymphoma or solid tumors raise concerns for immune modulation accelerating progression; long-term safety data show slight malignancy increase vs. placebo.[1][2]
Vaccinations and Immunosuppression
Live vaccines are contraindicated during treatment. Comorbidities requiring immunosuppression (e.g., rheumatoid arthritis on biologics, organ transplant) heighten risks; avoid overlap. Postpone Cosentyx until 4-6 weeks after live vaccines.[1]
What Do Real-World Studies Show?
Observational data from registries like SCULPTURE and FUTURE trials report higher adverse events in patients with diabetes (infection rates up 20%) or cardiovascular disease (CV events in 2-3%). No direct contraindication, but monitor lipids and blood pressure.[3][5]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: Papp KA et al., Lancet 2013;381:1095-1103
[4]: EMA Summary of Product Characteristics
[5]: Mease PJ et al., Ann Rheum Dis 2018;77:890-897